{"id":"i-v-cefuroxime-750-mg-3-d-for-2-days","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Diarrhea"},{"rate":"1-2%","effect":"Nausea"},{"rate":"1-3%","effect":"Phlebitis at injection site"},{"rate":"1-3%","effect":"Hypersensitivity reactions"},{"rate":"1%","effect":"Headache"},{"rate":"1%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1436","moleculeType":"Small molecule","molecularWeight":"424.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefuroxime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against a wide range of infections. The intravenous formulation allows for rapid systemic distribution and is commonly used for serious infections requiring high serum concentrations.","oneSentence":"Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:48.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, bone and joint, meningitis, septicemia)"},{"name":"Perioperative prophylaxis in surgical procedures"}]},"trialDetails":[{"nctId":"NCT02819570","phase":"PHASE4","title":"Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2015-11","conditions":"Premature Rupture of Membrane","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"I.V cefuroxime 750 mg*3/d for 2 days","genericName":"I.V cefuroxime 750 mg*3/d for 2 days","companyName":"Western Galilee Hospital-Nahariya","companyId":"western-galilee-hospital-nahariya","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, bone and joint, meningitis, septicemia), Perioperative prophylaxis in surgical procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}